Business Context and Reporting Period
This Form 8-K filing by Mustang Bio, Inc. (MBIO) reports on events occurring on December 17, 2025, and the results of the 2025 Annual Meeting of Stockholders held on December 22, 2025. The company is a biopharmaceutical firm focused on developing cell therapies, headquartered in Waltham, Massachusetts.
Key Financial Metrics
This filing is a current report regarding corporate governance and specific contractual events; it does not provide comprehensive financial statements, revenue, profit, cash flow, margins, or debt levels for the reporting period.
Specific financial figures disclosed include:
- Settlement Payment: $730,000 paid to Fred Hutchinson Cancer Center to extinguish approximately $1.4 million in outstanding payables.
- Share Capital: As of the November 18, 2025 record date, 6,453,701 shares of Common Stock, 845,385 shares of Class A Common Stock, and 250,000 shares of Class A Preferred Stock were outstanding and eligible to vote.
Material Changes and Corporate Actions
The filing details two primary material events:
- Termination of CD20 License Agreement: On December 17, 2025, Mustang Bio terminated its 2017 License Agreement with Fred Hutchinson Cancer Center regarding its CD20 CAR-T program.
- The company settled outstanding obligations by paying $730,000 against $1.4 million in payables.
- A "look-back" provision was established: If Fred Hutch licenses the CD20 IP to a third party within three years, Mustang Bio is entitled to at least 10% of the consideration received.
- 2025 Annual Meeting Results: Approximately 58% of votes were represented, constituting a quorum. All four proposals were approved:
- Proposal 1: Election of seven directors (Michael S. Weiss, Manuel Litchman, Lindsay A. Rosenwald, Neil Herskowitz, David Jin, Adam Chill, and Michael Zelefsky).
- Proposal 2: Ratification of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025.
- Proposal 3: Amendment to the 2019 Employee Stock Purchase Plan (ESPP) to increase issuable shares by 250,000 and shares subject to a Purchase Right to 10,000.
- Proposal 4: Amendment to the 2016 Incentive Plan (EIP) to increase issuable shares by 2,500,000.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking revenue projections, or management commentary on future operational outlook beyond the specific events reported.
Risks and Contingencies:
- Intellectual Property Strategy: The termination of the CD20 License Agreement alters the company's IP landscape for its CD20 CAR-T program. While the company retains a potential 10% royalty on future third-party licenses granted by Fred Hutch, it no longer holds the primary license.
- Liquidity Impact: The immediate cash outflow of $730,000 for the settlement is noted, though the filing does not quantify the impact on overall liquidity.
Investor Verification Checklist
- Verify the impact of the CD20 License Agreement termination on the company's pipeline and future revenue potential for that specific program.
- Review the 2025 Definitive Proxy Statement (Schedule 14A) for detailed biographies of the newly elected directors and the full terms of the ESPP and EIP amendments.
- Confirm the company's current cash position and liquidity status in the most recent 10-Q or 10-K to assess the significance of the $730,000 settlement payment.
- Monitor future filings for any third-party licensing activity by Fred Hutch regarding CD20 IP that would trigger the 10% royalty obligation.